Proficio Capital Partners LLC acquired a new position in shares of Repligen Co. (NASDAQ:RGEN - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 21,303 shares of the biotechnology company's stock, valued at approximately $3,066,000.
Several other hedge funds and other institutional investors have also recently bought and sold shares of the company. Oppenheimer & Co. Inc. acquired a new stake in Repligen during the fourth quarter worth about $216,000. Amalgamated Bank boosted its stake in shares of Repligen by 1.0% in the fourth quarter. Amalgamated Bank now owns 25,114 shares of the biotechnology company's stock valued at $3,615,000 after purchasing an additional 238 shares during the period. Keeler Thomas Management LLC boosted its stake in shares of Repligen by 68.9% in the fourth quarter. Keeler Thomas Management LLC now owns 8,979 shares of the biotechnology company's stock valued at $1,294,000 after purchasing an additional 3,662 shares during the period. Handelsbanken Fonder AB boosted its stake in shares of Repligen by 8.9% in the fourth quarter. Handelsbanken Fonder AB now owns 14,633 shares of the biotechnology company's stock valued at $2,106,000 after purchasing an additional 1,200 shares during the period. Finally, Global Retirement Partners LLC lifted its stake in Repligen by 54.0% in the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock worth $53,000 after acquiring an additional 129 shares during the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
RGEN has been the subject of a number of recent research reports. HC Wainwright reiterated a "buy" rating and issued a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. Canaccord Genuity Group lifted their price target on shares of Repligen from $165.00 to $170.00 and gave the stock a "hold" rating in a research note on Friday, February 21st. Wolfe Research initiated coverage on shares of Repligen in a research note on Thursday, November 14th. They issued a "peer perform" rating for the company. Royal Bank of Canada lifted their price target on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. Finally, StockNews.com downgraded shares of Repligen from a "hold" rating to a "sell" rating in a research note on Friday, February 21st. One research analyst has rated the stock with a sell rating, five have issued a hold rating and eight have given a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $181.00.
Check Out Our Latest Stock Report on RGEN
Repligen Stock Performance
Shares of Repligen stock traded down $4.41 during trading on Friday, reaching $155.70. The company's stock had a trading volume of 923,847 shares, compared to its average volume of 618,521. The company has a 50-day moving average price of $157.23 and a two-hundred day moving average price of $148.62. The firm has a market cap of $8.72 billion, a PE ratio of -305.29, a P/E/G ratio of 4.54 and a beta of 0.95. Repligen Co. has a fifty-two week low of $113.50 and a fifty-two week high of $203.13. The company has a current ratio of 10.44, a quick ratio of 8.76 and a debt-to-equity ratio of 0.26.
Repligen (NASDAQ:RGEN - Get Free Report) last announced its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 EPS for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. The business had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. On average, analysts forecast that Repligen Co. will post 1.72 EPS for the current year.
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
Further Reading
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
